Proteome Sciences's revenue for the
six
months ended in Dec. 2025 was $2.54 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $5.06 Mil.
Proteome Sciences's Revenue per Share for the
six
months ended in Dec. 2025 was $0.01.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.
Warning Sign:
Proteome Sciences PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Proteome Sciences was -25.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -21.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -5.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Proteome Sciences's highest 3-Year average Revenue per Share Growth Rate was 212.40% per year. The lowest was -43.50% per year. And the median was 10.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Proteome Sciences Revenue Related Terms
Proteome Sciences Revenue Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Proteome Sciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences Revenue vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Revenue distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences (PMSNF) has a Revenue of $5.06 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Proteome Sciences and its competitors.
Is Proteome Sciences' Revenue too high?
Proteome Sciences' current Revenue is $5.06 Mil.
How does Proteome Sciences' Revenue compare to TMO and DHR?
Proteome Sciences' Revenue of $5.06 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Diagnostics & Research company?
A good Revenue depends on the Medical Diagnostics & Research industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Proteome Sciences and its competitors. Proteome Sciences's current Revenue is $5.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Proteome Sciences (PMSNF) has a current Revenue of $5.06 Mil. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 17.5% below its estimated fair value. The current Revenue is $5.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current Revenue is $5.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMSNF has been successfully added to your 